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Abstract: Within the ovarian cancer tumor microenvironment, cancer stem-like cells (CSC) interact
with carcinoma associated mesenchymal stem/stromal cells (CA-MSC) through multiple secreted
cytokines and growth factors. These paracrine interactions have been revealed to cause enrichment of
CSC and their chemoprotection; however, it is still not known if platelet-derived growth factor (PDGF)
signaling is involved in facilitating these responses. In order to probe this undiscovered bidirectional
communication, we created a model of ovarian malignant ascites in the three-dimensional (3D) hanging
drop heterospheroid array, with CSC and CA-MSC. We hypothesized that PDGF secretion by CA-MSC
increases self-renewal, migration, epithelial to mesenchymal transition (EMT) and chemoresistance in
ovarian CSC. Our results indicate that PDGF signaling in the CSC-MSC heterospheroids significantly
increased stemness, metastatic potential and chemoresistance of CSC. Knockdown of PDGFB in
MSC resulted in abrogation of these phenotypes in the heterospheroids. Our studies also reveal
a cross-talk between PDGF and Hedgehog signaling in ovarian cancer. Overall, our data suggest
that when the stromal signaling via PDGF to ovarian CSC is blocked in addition to chemotherapy
pressure, the tumor cells are significantly more sensitive to chemotherapy. Our results emphasize the
importance of disrupting the signals from the microenvironment to the tumor cells, in order to improve
response rates. These findings may lead to the development of combination therapies targeting
stromal signaling (such as PDGF and Hedgehog) that can abrogate the tumorigenic, metastatic and
platinum resistant phenotypes of ovarian CSC through additional investigations.
Keywords: ovarian cancer; cancer stem-like cells (CSC); carcinoma associated mesenchymal stem
cells (CA-MSC); platelet derived growth factor (PDGF); stemness; chemoresistance; high grade serous
ovarian cancers; 3D spheroids; tumoroids; heterospheroids; stromal cells
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1. Introduction
Ovarian cancer is the fifth leading cause of cancer-related deaths in women in the United States,
and has a low survival rate, due in part to the frequent late stage at diagnosis [1,2]. Despite aggressive
surgical debulking and first-line platinum-based therapy, a ~70% relapse rate is observed, attributable
to chemoresistance and peritoneal metastasis [1]. Chemoresistance and new tumor growth following
primary therapy has been ascribed to ovarian cancer stem cells (CSC), through a complex interplay with
other cells within the tumor microenvironment (TME) [1,3–7]. Previous studies have indicated that CSC
in ovarian cancer are identified with high CD133 expression and increased aldehyde dehydrogenases
(ALDH) activity, and presence of these cells predicts prognosis for reduced progression-free survival
and poor patient outcome [8–21]. Additionally, elevated ALDH activity alone has been utilized in
previous studies as a marker of the CSC progenies [8–21].
Stromal cells within the TME, including carcinoma-associated mesenchymal stem/stromal
cells (CA-MSC) play critical supportive roles aiding in CSC proliferation, metastasis and
chemoresistance [22–25]. CA-MSC arise from tumor mediated reprograming of local tissue MSC,
and have been linked to increased tumorigenesis and chemoresistance through secretion of a complex
cytokine network involving IL-6, SDF-1, TGF-β, BMP2, BMP4 and CCL5 [22,23,26–28]. Co-culture of
ovarian cancer cells with MSC leads to increased proliferation, invasiveness and platinum resistance
of the cancer cells [29,30]. Additionally, ovarian CSC and CA-MSC are known to communicate
bi-directionally, with CSCs possessing the ability to impact the phenotype of MSCs to make them
more tumor-supportive [26]. Within the framework of this dynamic CSC/CA-MSC relationship,
we hypothesize that platelet-derived growth factor (PDGF) plays a critical role in CSC/CA-MSC
pro-tumorigenic signaling.
The PDGF family has been shown to play a crucial role in MSC differentiation and growth [31]
and can protect MSC from apoptosis and senescence [32]. Additionally, in ovarian cancers, PDGF
ligands, including PDGF-BB, and their corresponding receptors (PDGFR) have been noted as a
potential key pathway with poor prognosis, yet PDGF signaling is poorly studied in the context
of ovarian CSC/CA-MSC interactions [33–36]. PDGFR are known to promote CSC phenotypes in
sarcomas [37]. PDGF signaling has also been linked to the formation and maintenance of glioma, gastric
cancer, lung cancer and breast cancer, among others [38–43]. Downstream of the PDGF-BB/PDGFR
interaction, several mechanistic pathways have been shown to increase tumorigenicity, metastasis
and CSC phenotypes. Among those documented are the epithelial to mesenchymal transition (EMT)
pathway in several cancers, as well as the Hedgehog (HH) signaling pathway [44–47]. Importantly,
the multitargeted tyrosine kinase inhibitor, sunitinib and Hedgehog signaling pathway (Smoothened)
inhibitor, sonidegib, have been explored in randomized phase II settings, demonstrating moderate
single agent efficacy in targeting stromal components in ovarian and other cancers [48–54].
In this study, we utilized a three-dimensional (3D) hanging drop array spheroid platform, to bring
CSC and human adipose MSC (MSC) or carcinoma-associated primary MSC (CA-MSC) in close
association in a non-adherent 3D in vitro structure, similar to their presence and interactions within
the malignant ascites [19,50,55–58]. Using this model, we aimed to investigate the hypothesized
PDGF-BB/PDGFR-β signaling and its downstream effects on functional CSC behaviors, including
migratory potential, tumorigenicity and platinum resistance. In addition, we evaluated the role of
PDGF-BB/PDGFR-β interactions in promoting EMT and/or Hedgehog signaling, and their effect on
the metastatic and tumorigenic CSC phenotype. Overall, coupled with the importance of PDGF as
a prognostic marker for ovarian cancer, we believe that disrupting the trophic signaling between
CA-MSC and CSC by inhibiting PDGF signaling is a novel therapeutic avenue of investigation to
reduce platinum resistance in ovarian cancers.
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2. Results
2.1. Characterization of CSC/MSC Heterospheroids
CSC/MSC heterospheroids (either human ovarian carcinoma OVCAR3/MSC or matched patient
CSC/CA-MSC) were generated and observed to form compact, intact spheroids in hanging drop cultures
by 4 days (Figure 1A). At Day 5, heterospheroids were harvested to characterize the presence of MSC
within them using CD73. Flow analysis protocols were adapted from our previous studies [19–21,55,56],
and gating strategy for each antibody and its associated FMO isotype are demonstrated in Figures S1–S4.
Representative flow analysis plots (Figure 1B) indicate the presence of a CD73+ population within
heterospheroids. Further quantification indicated the robust presence of a 5–20% CD73+ MSC
population within heterospheroids at Day 5 (Figure 1C). As seen in Figure S1, CSC did not express CD73.
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Figure 1. Characterization of L /CD133+ cancer stem-like cells ( SC)/carcinoma associated
mesenchymal stem cell (CA-MSC) heterosp s ith fluorescence activat d cell sorting (FACS).
(A) Phase contras micrographs of (i) OVC / SC, (ii) Patient 1 SC/CA-MSC and (ii ) Patient
2 CSC/CA-MSC heterospheroids showing compact spheroids following 4 days in hanging drop culture.
(B) Representative flow cytometry plots quantifying the presence of CD73+ MSC within heterospheroids
(i) OVCAR3 CSC/MSC, (ii) Patient 1 CSC/CA-MSC and (iii) Patient 2 CSC/CA-MSC heterospheroids at
Day 5. See Supplementary Figures S1–S4 for gating strategies. (C) Graphical representation of flow
cytometry analysis data, quantifying the presence of CD73+ MSC within heterospheroids, ranging
from ~5% to 27% (n ≥ 3).
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2.2. CSC/MSC Heterospheroids Demonstrate a Platinum-Resistant Phenotype, Enriched with ALDH+ Cells
To assess the impact of MSC on cancer cell stemness, we evaluated aldehyde dehydrogenase
(ALDH) activity within heterospheroids as a marker of CSC, consistent with our prior work [28].
Previous work has established ovarian cancer cells that express CD133 highly and have elevated ALDH
activity, as the ALDH+ CD133+ CSC, which are at the apex of the CSC hierarchy [8,9,11,18–21,55,59].
These CSC and can self-renew and asymmetrically divide to create daughter progenies that are either
ALDH+ or CD133+. Therefore, ALDH+ population contains both CD133+ and CD133− cancer cells.
We found significant increase in ALDH+ cells in CSC/MSC heterospheroids when compared to CSC
mono-spheroids (Figure 2A,B). Significant enhancement in ALDH+ cells (* p < 0.05, ** p < 0.001,
two-way ANOVA) was observed between OVCAR3 CSC and OVCAR3 CSC/MSC spheroids, as well as
Patient 1 and Patient 2 CSC/CA-MSC spheroids. On average, the ALDH+ cells increased by ~1.5-fold
in CSC/MSC spheroids compared to CSC spheroids alone (Figure 2B). As seen in Figure S2C, MSC did
not express ALDH.
Given the elevation in ALDH activity suggestive of increased stemness, we tested the impact of
MSC on carboplatin sensitivity in CSC/MSC heterospheroids. We observed a significant elevation in
carboplatin IC50 in CSC/MSC spheroids compared to CSC spheroids alone, in the spheroids based on
OVCAR3 and primary patient samples. Representative images of control and drug treated spheroids
at 100 µM carboplatin indicate the loss of boundary integrity and toxicity induced by drug treatment
(Figure 2C). Carboplatin IC50 plot for each sample (Figure 2D) demonstrates significant changes
in CSC/MSC spheroids. Similar to our previous observation [22], heterospheroids that contained
MSC or CA-MSC were significantly more chemoresistant to carboplatin treatment, with higher IC50
values compared to CSC-only spheroids (Figure 2E). Given the heterogeneity in the patient samples,
the IC50 values differed significantly between the heterospheroids generated with the OVCAR3
CSC and patient-derived CSC. These results are expected based on the previous characterization of
patient-derived heterogeneity in the hanging drop spheroids [18–21,55].
2.3. Knockdown of MSC-Derived PDGFB Reveals the Critical Significance of PDGF-BB/PDGFR-β Signaling in
Platinum Resistance and CSC Enrichment
We hypothesized that PDGF-BB/PDGFR-β signaling may be a critical pathway involved in
CSC/MSC interactions. To determine the impact of MSC PDGF signaling on platinum resistance,
we proceeded to knock down PDGFB in MSC using siRNA. Gene expression analysis indicated that
siPDGFB MSC had a 74% knockdown of PDGFB at 96 h, compared to no knockdown in scrambled
siRNA (SCR) control MSC (** p < 0.001, one-way ANOVA) (Figure 3A), without significant change to
viability. Heterospheroids were generated from CSC/siPDGFB MSC to understand changes in platinum
resistance and percentage of ALDH+ cells upon knock-down of MSC-derived PDGF-BB. PDGFR-β
gene expression was significantly reduced in CSC in CSC/siPDGFB MSC heterospheroids (** p < 0.001,
one-way ANOVA) (Figure 3B). Increase in percent ALDH+ cells observed in SCR MSC heterospheroids
was significantly reduced in CSC/siPDGFB MSC spheroids (* p < 0.05, one-way ANOVA; Figure 3C).
Along with the significantly reduced percentage of ALDH+ cells, we also observed an increased
sensitivity to carboplatin treatment, evidenced by the decreased IC50 values in CSC/siPDGFB MSC
heterospheroids (46.2 µM compared to 66.3 µM in CSC/SCR MSC; Figure 3D). Heterospheroids
generated from modified MSC were phenotypically very similar to unmodified MSC on phase contrast
images (Figure 3E).
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Figure 2. Co-culture of ovarian CSC with MSC leads to increased stemness and platinum resistance.
(A) Representative flow cytometry plots of ALDH+ cells in (i) OVCAR3 CSC/MSC, (ii) Patient 1
CSC/CA-MSC and (iii) Patient 2 CSC/CA-MSC heterospheroids. (B) Graphical representation of
ALDH+ flow cytometry analysis between CSC monospheroids, and CSC/MSC heterospheroids indicate
a significant increase in ALDH+ populations in heterospheroids (* p < 0.05, ** p < 0.001, two-way
ANOVA, ≥ 3). (C) Phase co trast micrographs of (i) OVCAR3 CSC/MSC, (ii) Patient 1 CSC/CA-MSC
and (iii) Patient 2 CSC/CA-MSC Day 5 heterospheroids treated with 100 µM of carbopl tin or control
untreated for 48 h. Images indicate a loss of boundary integrity and cell death within carboplatin treated
spheroids, compared to untreated spheroids at the same time-point. (D) Graphical representation of
IC50 plots derived from cell viability quantification, demonstrating that CSC/MSC heterospheroids
demonstrate an increased IC50 to carboplatin compared to CSC monospheroids (n ≥ 3). (E) Tabulation
of changes in IC50 values with MSC/CA-MSC co-culture.
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Figure 3. CSC platinum resistance and CSC enrichment can be reduced with PDGFB knockdown in
MSC. (A) Fold change in PDGFB gene expression in MSCs treated with scrambled siRNA (SCR) or
PDGFB siRNA (siPDGFB) was quantified with qPCR showing a significant decrease with siPDGFB
(** p < 0.001, one-way ANOVA, n ≥ 3). (B) Gene expression of the receptor, PDGFRB in OVCAR3 CSCs
was decreased significantly when co-cultured with siPDGFB MSCs compared to CSC mono-cultures
(** p < 0.001, one-way ANOVA, n ≥ 3). (C) Flow cytometry of ALDH expression in OVCAR3 CSCs
showed a decrease in ALDH+ cells when co-cultured with siPDGFB MSCs (* p < 0.05, one-way ANOVA
followe by Tukey’s test, n ≥ 3). (D) Quantifi ation of the IC50 changes using an MTS assay of OVCAR3
CSCs cultur with SCR or siPDGFB MSCs showing a reduction in 50 (n ≥ 3). (E) Representative
optical microscopy images of (i) OVCAR3 CSC/SCR MSC without drug treatment, (ii) OVCAR3
CSC/SCR MSC treated with 100 µM carboplatin, (iii) OVCAR3 CSC/siPDGFB MSC without drug
treatment and (iv) OVCAR3 CSC/siPDGFB MSC treated with 100 µM carboplatin.
2.4. PDGF-BB/PDGFR-β Signaling Is Significantly Involved in CSC/MSC Interactions Leading to the
Development of Platinum Resistance
Given that we found PDGF-BB/PDGFR-β signaling to be a critical pathway involved in CSC/MSC
interactions, we next tested interactions between soluble ligand and its receptor. In order to test
the presence of PDGF-BB as a soluble factor within the CSC/MSC microenvironment, we performed
an enzyme-linked immunosorbent assay (ELISA), where we found that OVCAR3 CSC cultures in
CSC/MSC heterospheroids demonstrated an increased presence of PDGF-BB that was not statistically
significant (Figure 4A). In order to test for PDGFR-β receptor expression in CSC, we extracted RNA
from OVCAR3 CSC cultured as mono-spheroids or within CSC/MSC heterospheroids. CSC from
heterospheroids were sorted by flow cytometry (for ALDH activity) before RNA isolation, to avoid
Cancers 2020, 12, 2063 7 of 21
obtaining a signature from MSC. Our data indicate that upon MSC co-culture, CSCs significantly
(*** p < 0.0001, unpaired t-test; Figure 4B) upregulate PDGFR-β expression (over two-fold).Cancers 2020, 12, x 8 of 23 
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CSC co-cultured with MSCs compared to OVCAR3 CSC mono-cultures. (C) PDGFR-β expression was
confirmed using flow cytometry, and in corroboration with qPCR data, demonstrated a non-significant
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by Tukey’s test, n ≥ 3). (D) Representative flow cytometry plots from the quantification in (C). (E) CSC
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We also analyzed PDGFR-β receptor expression using flow cytometry, and observed that CSC/MSC
heterospheroids had a significantly elevated expression of PDGFR-β, compared to CSC mono-spheroids
(* p < 0.05, one-way ANOVA with Tukey’s test; Figure 4C). Representative flow analysis plots for
PDGFR-β expression are shown (Figure 4D). To inhibit the increased PDGF-BB/PDGFR-β signaling
within CSC/MSC heterospheroids, we used sunitinib, which blocks PDGFR-β among other tyrosine
kinases. Low dose sunitinib partially reversed MSC driven increases in chemotherapy resistance with
a sub-cytotoxic dose of 5 µM, with IC50 39–50 µM (Figure 4E,F) in the presence of sunitinib, compared
to 67–153 µM without sunitinib (Figure 2D,E). Table S1 lists the carboplatin IC50 across all comparison
groups, with and without sunitinib.
2.5. EMT Phenotype Observed Downstream of PDGF-BB/PDGFR-β Interactions in CSC
Increases in EMT transcription markers such as TWIST, SNAIL, ZEB1 and ZEB2 have been
linked to increased migration and metastasis, and has previously been linked to PDGF [60,61].
We observed a significant upregulation (>two-fold) of several transcription factors associated with the
EMT phenotype in OVCAR3 CSC cultured within CSC/MSC heterospheroids (Figure 5A). The same
genes were significantly downregulated in CSC/siPDGFB MSC conditions (*** p < 0.0001, two-way
ANOVA) (Figure 5B), indicating the partial loss of the EMT phenotype upon loss of PDGF-BB/PDGFR-β
signaling. Concurrent with upregulation of EMT genes, we observed that CSC/MSC and CSC/SCR
MSC heterospheroids were significantly (* p < 0.05, one-way ANOVA) more migratory in a transwell
setting, and this migration could be inhibited using the PDGFR-β inhibitor sunitinib or by inhibiting
the secretion of PDGF-BB from MSC using siPDGFB MSC within heterospheroids (Figure 5C).
Representative fluorescent micrographs are demonstrated in Figure 5D corresponding to the various
conditions tested for migration.
2.6. Hedgehog Is Activated Downstream of MSC-Derived PDGFB in CSC
We previously showed that MSC induce Hedgehog signaling in CSC [22]. To determine if the
PDGF-BB/PDGFR-β signaling was responsible for this alteration in Hedgehog pathway, we used qPCR to
observe changes in expression of the genes associated with the Hedgehog signaling pathway (Figure 6A).
We found that Hedgehog ligands SHH and IHH were significantly upregulated in CSC cultured in
heterospheroids with WT MSC, and this upregulation was diminished in CSC cultured with siPDGFB
MSCs (Figure 6A; **** p < 0.0001, two-way ANOVA). Similar patterns of gene expression were observed
for downstream targets of classical Hedgehog signaling, PTCH1, SMO (* p < 0.05, two-way ANOVA) and
GLI1 (* p < 0.05, two-way ANOVA), indicating the partial involvement of PDGF-BB signaling upstream of
Hedgehog ligand secretion in CSC within the CSC/MSC interaction paradigm. We additionally tested if this
cross-talk between PDGF-BB/PDGFR-β and Hedgehog signaling was synergistic by using a SMO inhibitor,
sonidegib, at sub-cytotoxic IC50 doses of 1 mM. Changes in Carboplatin IC50 are plotted in the presence of
sonidegib in Figure 6B, implying a significant cross-talk between the two tested pathways. Representative
phase contrast images of spheroids treated with carboplatin in the presence of sonidegib are shown in
Figure 6C. Table S1 lists the carboplatin IC50 across all comparison groups, with and without sonidegib.
2.7. Serial Passaging of CSC/MSC Spheroids Indicate CSC Enrichment
We have recently demonstrated that serially passaging ovarian cancer spheroids over 20 passages
increases their stemness, tumorigenicity and chemoresistance [21]. In order to observe any changes in
CSC enrichment modulated by co-culturing with MSC in heterospheroids, we serially passaged CSC/MSC
spheroids for three consecutive passages (Passage 0–2). Three-dimensional serial passaging did not diminish
the ability of CSC and MSC to form spheroids, as demonstrated by phase contrast images of spheroids at
Day 1 and Day 4 (Figure 7A). Flow analysis at each passage indicated the statistically significant increase in
ALDH+ cells within heterospheroids with serial passaging (** p < 0.001, two-way ANOVA), similar to our
previous serial passage work [47], and a significant increase in PDGFR-β expression (* p < 0.05, two-way
ANOVA). No changes in CD73 expression were noted, implying the steady maintenance of ~20% of the
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heterospheroid population as MSC (Figure 7B). Furthermore, no significant changes in proliferation were
observed in heterospheroids with serial passaging (Figure 7C).Cancers 2020, 12, x 10 of 23 
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bar = 100 µm. 
Figure 5. Downstream EMT Markers and Ch i igration of Ov rian SC. (A) G ne xpression
analysis of EMT markers in 3 CSCs c ltured with MSCs in het spheroids, compared to
CSC ono-cultures (red dotted line). A significant (>two-fold) increase in ge e-expression was
observed for several EMT markers tested (n ≥ 3). (B) Gene expression analysis of EMT markers
following CSC/siPDGFB MSC co-cultures demonstrated a significant downregulation (*** p < 0.0001,
two-way ANOVA, n ≥ 3) of EMT markers upon PDGFB knockdown. The red line indicates CSC
values. (C) Increased migration of OVCAR3 CSC was seen in a transwell assay when co-cultured with
MSC; this increase was negated with sunitinib treatment or PDGFB knockdown of MSCs (* p < 0.05,
one-way ANOVA, n ≥ 3). (D) Representative fluorescent images of migrated GFP+ CSC (green) in
a transwell assay after 5 days of co-culture showing (i) OVCAR3 SCs cultured alone, (ii) OVCAR3
CSC/MSC, (iii) OVCAR3 CSC/SCR MSC and (iv) OVCAR3 SC/siPDGFB MSC where more migrated
cells are seen with MSC culture and siPDGFB reduces the effect MSCs have on CSC migration (n ≥ 3).
Scale bar = 100 µm.
Cancers 2020, 12, 2063 10 of 21
Cancers 2020, 12, x 11 of 23 
2.6. Hedgehog Is Activated Downstream of MSC-Derived PDGFB in CSC 
We previously showed that MSC induce Hedgehog signaling in CSC [22]. To determine if the 
PDGF-BB/PDGFR-β signaling was responsible for this alteration in Hedgehog pathway, we used 
qPCR to observe changes in expression of the genes associated with the Hedgehog signaling pathway 
(Figure 6A). We found that Hedgehog ligands SHH and IHH were significantly upregulated in CSC 
cultured in heterospheroids with WT MSC, and this upregulation was diminished in CSC cultured 
with siPDGFB MSCs (Figure 6A; **** p < 0.0001, two-way ANOVA). Similar patterns of gene 
expression were observed for downstream targets of classical Hedgehog signaling, PTCH1, SMO (* p 
< 0.05, two-way ANOVA) and GLI1 (* p < 0.05, two-way ANOVA), indicating the partial involvement 
of PDGF-BB signaling upstream of Hedgehog ligand secretion in CSC within the CSC/MSC 
interaction paradigm. We additionally tested if this cross-talk between PDGF-BB/PDGFR-β and 
Hedgehog signaling was synergistic by using a SMO inhibitor, sonidegib, at sub-cytotoxic IC50 doses 
of 1 mM. Changes in Carboplatin IC50 are plotted in the presence of sonidegib in Figure 6B, implying 
a significant cross-talk between the two tested pathways. Representative phase contrast images of 
spheroids treated with carboplatin in the presence of sonidegib are shown in Figure 6C. Table S1 lists 
the carboplatin IC50 across all comparison groups, with and without sonidegib. 
 
Figure 6. Downstream Activation of Hedgehog through PDGF-BB/PDGFR-β Signaling in Ovarian CSC
and MSC Crosstalk. (A) Gene expression analysis of Hedgehog pathway elements in OVCAR3 CSC
mono-cultures (black line), OVCAR3 CSC/MSC or OVCAR3 CSC/siPDGFB MSC heterospheroids. Gene
qPCR data demonstrates a significant loss in Hedgehog ligands (SHH and IHH; **** p < 0.0001, two-way
ANOVA, n ≥ 3) upon PDGFB knockdown. Additionally, signaling elements within the Hedgehog
pathway are also significantly downregulated (* p < 0.05, two-way ANOVA) upon PDGF knockdown
including Smoothened (SMOO) and GLI1, indicating that PDGFB might be upstream of Hedgehog
ligand secretion and/or signaling (n ≥ 3). (B) OVCAR3 CSC/MSC and OVCAR3 CSC/siPDGFB MSC
heterospheroids were treated with 1 mM sonidegib, a Smoothened inhibitor, and carboplatin to
determine the change in IC50. Hedgehog inhibition compounded with knockdown of PDGFB, resulting
in a lower carboplatin IC50 in CSC/MSC heterospheroids (n ≥ 3). (C) Representative phase contrast
microscopy images of the heterospheroids when treated with 1 mM sonidegib and 100 µM carboplatin,
indicating significant visual cell death and loss of spheroid integrity.
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Figure 7. MSC Support the Enrichment of CSC due t Serial Passagin . (A) Representative optical
microscopy images of CSC/MSC heterospheroids on Day 1 and Day 4, Passage 0–2. (B) Quantification of
the change in ALDH+, PDGFR-β and CD73+ cell populations with FACS in each passage. An increase
over passage number is seen in ALDH and PDGFR-β but the CD73 population remains constant
(* p < 0.05, ** p < 0.001, two-way ANOVA, n ≥ 3). (C) Proliferation quantified on Day 0 and Day 4 was
consistent across three passages (paired t-test, n ≥ 3).
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3. Discussion
Ovarian CSC are implicated in platinum resistance, disease recurrence and metastasis, leading to
increased tumorigenicity and disease relapse. CSC harness the power of the tumor microenvironment
(TME), including carcinoma associated mesenchymal stem cells (CA-MSC), among other stromal
cells, to achieve their tumorigenic goals. The presence of CA-MSC contribute specifically to platinum
resistance via multiple documented signaling pathways and mechanisms [22,29,62]. Well-established
cytokine/chemokine networks exist to indicate how CA-MSC communicate with CSC and promote
tumorigenesis and metastasis [11–13].
Here, we explored a novel link between the two cell types in the ovarian cancer TME, previously
unknown in its involvement in CSC/CA-MSC communication, namely the PDGF-BB/PDGFR-β signaling
pathway. De-regulation of PDGF-BB/PDGFR-β signaling is implicated in driving tumorigenesis and
metastasis in several cancers [63–65]. PDGF-BB, the principal ligand for the PDGFR-β receptor,
is significantly elevated in malignant ascites compared to non-malignant peritoneal fluid. In fact,
targeting the PDGF receptors has been shown to inhibit PDGF-induced receptor activation and cell
proliferation in ovarian cancer cells [66].
We found PDGFR-β receptor expression is upregulated in CSC co-cultured with MSC, likely in
response to paracrine stimulation from PDGF-BB secretion by MSC. In the context of platinum resistance,
our results clearly demonstrate that removing PDGF-BB from the shared CSC/MSC microenvironment
through gene knockdown or inhibiting PDGF-BB/PDGFR-β interactions through sunitinib significantly
improves sensitivity to carboplatin. This is generally in line with evidence in colorectal and other
carcinomas where CA-MSC increase platinum resistance through a variety of mechanisms [22,29,62].
Our work demonstrates the specific involvement of the growth factor PDGF-BB in this platinum
resistance phenomenon, in line with other described roles of PDGF signaling in ovarian and other
cancers in their interaction with mesenchymal stroma [36,37,67]. Furthermore, in line with established
literature, we observe an increase in the percentage of ALDH+ CSC in the heterospheroids, with an
associated increase in EMT signatures, and functional migration [40,41,43,44,46,47,66]. PDGF signaling
has been related to increased EMT markers such as TWIST, SNAIL, ZEB1 and ZEB2 through several
pathways in cancer cell-MSC interactions [44,47,68,69].
The Hedgehog signaling pathway has been well-documented to promote platinum resistance
and tumorigenesis of epithelial ovarian tumors, even posing as an attractive therapeutic target [70,71].
Our results indicate that CSC/MSC interactions increase the secretion of Hedgehog ligands, consistent
with the bi-directional communication paradigm resulting in increased percentage of ALDH+ CSC
via MSC-secreted BMP-4 [9]. Our studies further reveal the putative upstream involvement of
PDGF-BB/PDGFR-β potentiating CSC/MSC Hedgehog signaling through PTCH, SMO and GLI1,
all documented to result in platinum resistance of ovarian cancer [6,22,45,72]. Knockdown of
MSC-derived PDGF-BB results in a significant loss of Hedgehog ligands (SHH, IHH) and pathway
elements (PTCH, SMO, GLI1) in the CSC compartment, wholly implicating PDGF-BB to be a potent
upstream regulator of Hedgehog signaling. Paracrine PDGF-BB is implicated upstream of Hedgehog,
resulting in migration and cytoprotection in non-cancerous muscle cells, and several cancers including
gliomas and cholangiocarcinomas [45,73–75]. Through our results, we therefore propose a novel
cross-talk between PDGF-BB/PDGFR-β interactions and Hedgehog signaling in ovarian cancer,
which can lead to the development of a tumorigenic, metastatic and platinum resistant phenotype
within CSC, driven partially by MSC-secreted PDGF-BB (Figure 8).
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Figure 8. Hypothesized mechanism of PDGF-BB/PDGFR-β communication between ovarian CSC
and CA-MSC with Hedgehog downstream signaling. PDGF-BB is secreted by CA-MSC and binds to
PDGFR-β receptor, which are expressed by ovarian CSC. Binding between PDGFR-β and PDGF-BB
directly causes an increase in CSC markers, platinum resistance and EMT markers in ovarian CSC.
Additionally, PDGF-BB binding is shown to be upstream of Hedgehog as it leads to an increase in
Hedgehog ligand secretion. Hedgehog is known to also cause an increase in CSC markers, platinum
resistance and EMT markers in ovarian CSC through PTCH, SMO and GLI1. Treatment with sunitinib,
a PDGFR-β inhibitor, leads to decrease in the CSC and EMT marker expression, and increase in
sensitivity to platinum. These phenotypes are direct result of inhibition of the PDGF-BB/PDGFR-β and
Hedgehog signaling pathways.
4. Materials and Methods
4.1. Materials
All tissue culture reagents (medium components, supplements) were purchased from Thermo
Fisher Scientifi (Waltham, MA, USA), unless otherwise specified. The OVCAR3 cell line was
purchased from Americ n Type Culture Coll ction (ATCC) (Waltham, MA, USA), and used under
Passage 40. Human adipose-derived m senchymal cells were also purchased from Thermo Fish
Scientific, and used within Passage 5. RNA interfer nce r agents we e purchased from Millipore
igma (St. Louis, MO, USA). Matched primary dissociat d live cryopreserved p tient sa ples fr m
hi h grade serous ovarian carcinoma were consented to Memo ial Sloan Kettering Cancer Center
IRB-approved biospecimen banking protocol and analyzed under an IRB-app oved biospecimen
use protocol. Sonid gib was gift from the l bor tor of Dr. Ch rlotte Mistretta at the University
of Mi higan School of Dentistry (Ann Arbor, MI, USA). The study was approved by the Memorial
Sloan Kettering Cancer Center Institutional Review Board (protocol 15-200, initial approval 8/21/2015,
continuing review approval 7/23/2019).
4.2. Isolation of Ovarian CSCs and CA-MSCs from Ovarian Cancer Patient Samples
CSC were isolated from the OVCAR3 cell line, or two high-grade serous ovarian carcinomas (Patient
1 and Patient 2), using protocols outlined previously [19,55–58]. Briefly, single cell suspensions were
incubated with ALDEFLUOR reagent (S em Cell Technologies, Vancouver, BC, Canada), and CD133
antibody. I this work, we define t e ‘ALDH+ cells’ as the ‘viable cells that possess high ALDH activity
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in the ALDEFLOUR FACS assay.’ ALDH+/CD133+ cells were isolated using fluorescent activated cell
sorting on the Beckman Coulter MoFlo Astrios, by trained technicians.
For CA-MSC from single cell tumor suspensions, cells were plated onto two-dimensional (2D)
tissue culture treated plates in an MSC selection medium following protocols outlined previously [28].
The medium consisted of basal MEBM (Lonza, Walkesville, MD, USA), supplemented with 20 ng/mL
EGF, bFGF, 1× B27, 5 µg/mL Insulin, 100 µM β-mercaptoethanol, 1 ng/mL hydrocortisone, 1×
antibiotics/antimycotics and 10% fetal bovine serum. Adherent cells were CA-MSC.
4.3. RNA Interference of PDGFB in MSC
Validated siRNA duplex constructs targeted against human PDGFB were purchased from
Sigma Aldrich (SASI_Hs01_00121961, SASI_Hs01_00121962, (St. Louis, MO, USA). Mission siRNA
Transfection reagent (Sigma Aldrich) was used to reverse transfect 10 nM of siRNA to MSC, in a 24-well
format following manufacturer’s protocols. A universal negative siRNA non-targeting control (Sigma
Aldrich) was utilized to rule out effects from transfection protocols. RNA was extracted from MSC
treated with siRNA (siPDGFB MSC) to assess the amount of knockdown via qPCR, outlined below.
4.4. Formation of Mono- and Heterospheroids from CSC and MSC
Mono- or heterospheroids were generated on an in vitro 384 well hanging drop array platform
as described previously [19,55–58]. Briefly, to generate CSC monospheroids, single cell suspensions
of CSC were diluted, in such a manner that a 20 µL drop contained 12 CSCs. For heterospheroids,
CSC and MSC were diluted in a 1:3 ratio, such that a 20 µL drop contained three CSCs and nine MSCs.
Spheroids were cultured in a 1:1 medium mixture of RPMI and ADSC-BM (Lonza) supplemented with
1% penicillin/streptomycin and 1% L-glutamate. Live cell imaging using phase contrast microscopy was
utilized to follow the formation of CSC or CSC/MSC spheroids. Spheroids were generated from CSCs
isolated from the OVCAR3 cell line, or OVCAR3 CSCs with human adipose MSC (MSC). Two matched
patient samples (Patient 1 and Patient 2) were also utilized to generate CSC/CA-MSC spheroids.
Additionally, heterospheroids were manufactured from CSC and siPDGFB MSC, in order to assess
changes in platinum resistance and CSC characteristics within heterospheroids. CSCgfp/siPDGFB MSC
heterospheroids were also generated, to be able to isolate the CSCgfp compartment using fluorescent
activated cell sorting using protocols described previously [20], for subsequent qPCR analysis.
4.5. Flow Cytometry Analysis
At the end of 4 days in spheroid culture, mono- or heterospheroids were harvested and resuspended
in FACS Buffer (PBS + 2% fetal bovine serum). The presence of MSC was determined by staining with
CD73. CSC were identified using elevated ALDH activity using the ALDEFLUOR Kit. The presence
of PDGFR-β (CD340) was assessed by staining with PDGFR-β antibody. Flow analysis protocols
were adapted from our previous studies [19–21,55,56], and gating strategies are demonstrated in
Supplementary Information Figures S1–S4.
4.6. Quantification of Cytokines Using ELISA
For ELISA assays, medium was harvested from 100 spheroids (CSC, CSC/CA-MSC spheroids).
ELISA assays were performed using the Duoset ELISA system (R&D Biosystems, Minneapolis MN)
following the manufacturer’s protocol, modified to include an overnight incubation. PDGF-BB was
analyzed using a standard curve, and a four parametric ELISA curve generation. ELISA assays and
data analysis were performed at the Immunological Monitoring Core at the Rogel Cancer Center,
University of Michigan (Ann Arbor, MI, USA).
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4.7. Assessment of Chemoresistance in Spheroids
Spheroids were generated from CSC, CSC/MSC or CSC/siPDGFB MSC and allowed to form until
Day 5. To identify changes in IC50 for carboplatin, spheroids were treated with a range of concentrations
of Carboplatin (10–200 µM) for 48 h. The MTS viability assay (Abcam, Cambridge, UK) was used to
determine viability of control untreated and carboplatin-treated spheroids, following manufacturer’s
protocols. Following a 1.5-h incubation of the MTS reagent with spheroids at 37 ◦C, absorbance
was read at 590 nm following manufacturer’s protocols. Results were quantified as normalized cell
viability, based on the viability of untreated control spheroids. Experiments were repeated with
three–five biological replicates for statistical analysis, and each experiment contained >20 technical
replicates. For combination drug doses, a range of carboplatin was utilized along with Sunitinib 5 µM,
or Sonidegib 1 mM, to identify changes in IC50.
4.8. Assessment of Migration in Spheroids
In order to quantify invasiveness of heterospheroids, 8 µm transwell inserts were placed in
each well of a 24-well plate. Ten CSCgfp or CSCgfp/MSC spheroids were harvested at Day 5 from
hanging drop arrays, and a single cell suspension was made. The cells were then FACS-sorted for the
GFP expression [20]. GFP-positive single cells were placed on the top chamber of a transwell insert.
The bottom chamber was filled with 400 µL of fresh medium, thus, only the bottom of the transwell
insert was immersed in medium. Following 3 days, the transwell insert was removed, and several
images of the bottom of the 24-well plate were obtained using fluorescent microscopy, identifying
GFP+ cells. Image J (U.S. National Institutes of Health, Bethesda, MD, USA) was used to quantify the
number of cells in a field of view. At least four random non-overlapping fields of view were counted
from each experiment, to find the number of cells that migrated through the transwell insert to the
bottom of the well.
4.9. Gene Expression Analysis via qPCR
RNA was extracted from spheroids or cells using the RNeasy extraction kit (Qiagen, Hilden,
Germany). Extracted RNA was assessed for concentration and purity using a Nanodrop 2000 (Thermo
Fisher Scientific) spectrophotometer. RNA was transcribed to cDNA using the High-fidelity cDNA
Transcription kit (Life Technologies, Carlsbad, CA, USA), and qPCR was carried out in a 96-well
format using 7900HT (Applied Biosystems, Foster City, CA, USA). Gene expression differences were
quantified using the 2∆∆CT method, using GAPDH as the housekeeping control, and reported as
fold change compared to a control sample. The following primers were utilized to test changes in
EMT: TWIST, SNAIL, ZEB1, ZEB2; the following primers were utilized to test PDGF signaling: PDGFB,
PDGFRB; the following primers were used to test Hedgehog signaling: PTCH1, SMOO, GLI1, GLI2,
SHH, IHH. A list of all primers used in qPCR is provided in Table S2.
For qPCR experiments, RNA was isolated from CSC mono-spheroids, or CSCs isolated based on a
GFP label from CSCgfp/MSC heterospheroids or CSCgfp/siPDGFB MSC spheroids. Control comparisons
were made with CSC mono-spheroids using the 2∆∆CT method, and fold changes are reported.
4.10. Serial Passaging of CSC/MSC Heterospheroids
In order to assess CSC enrichment, and predict tumorigenicity of CSC/MSC heterospheroids,
we utilized an in vitro serial passage model [20,21]. Passage 0 (P0) spheroids were generated using
protocols outlined in Section 4.4. Following 4–5 days of heterospheroid culture, spheroids were
harvested and CSC were isolated based on elevated ALDH activity using fluorescent activated cell
sorting. Isolated CSC were combined with MSC again and seeded into heterospheroids, and allowed
to remain in non-adherent hanging drop culture for 4–5 days. This process was repeated four
times, until a terminal passage of P3 was reached. At the end of each passage, spheroids were also
harvested to analyze the expression of ALDH activity, and PDGFR-β and the maintenance of a CD73+
Cancers 2020, 12, 2063 16 of 21
MSC population, using flow cytometry. Proliferation was assessed in spheroids by comparing MTS
absorbance in Day 1 compared to Day 4.
4.11. Data Analysis and Statistics
All experiments were performed with three–five biological replicates, with at least 20 technical
replicates for drug viability and at least three technical replicates for qPCR. Statistical analysis was
performed using GraphPad Prism 8 for Mac Os X (www.graphpad.com). Appropriate statistical tests
were performed and reported in each graph/figure legend, with asterisks indicating any significant
differences in test variables.
5. Conclusions
In conclusion, we have found PDGF-BB/PDGF-β to be an important signaling pathway between
CA-MSC and CSC in ovarian cancer, which has yet to be fully studied. We have linked PDGF-BB/PDGF-β
with increased stemness, metastatic potential and platinum resistance in ovarian CSC, acting in part
via canonical Hedgehog signaling. Inhibition of PDGF-BB/PDGF-β signaling was found to reduce
platinum resistance and metastatic potential development in ovarian CSC. Our findings suggest that this
PDGF-BB/PDGF-β pathway holds much interest for future studies in designing more effective therapies
for ovarian cancer. Overall, our report underscores the importance of TME signaling, and suggests
that in order to effectively target ovarian cancers, the tumor cells, as well as the supporting stromal
cells, are important, and need to be considered together.
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